A
Adcentrx Therapeutics
Adcentrx Therapeutics Inc.
About Adcentrx Therapeutics
Adcentrx Therapeutics, a clinical-stage biotechnology firm founded in 2021, is focused on the development of protein conjugate therapeutics for oncology and other severe diseases. The company was established by Dr. Hui Li, who currently serves as President and CEO, bringing over two decades of experience in drug discovery and business development within the biotech and pharmaceutical sectors. Before Adcentrx, Dr. Li was the CEO of Levena Biopharma, an antibody-drug conjugate (ADC) subsidiary of Sorrento Therapeutics, and held senior roles at PPD and Pfizer Global Research & Development. This extensive background in ADC development directly informs the company's strategic direction.
Adcentrx operates in the highly specialized market of antibody-drug conjugates, which are therapies that combine the precise targeting capabilities of antibodies with the potent cell-killing power of small molecule payloads. The company's business model is centered on advancing its proprietary pipeline of ADC candidates through clinical trials. Revenue generation is anticipated from the successful commercialization of these therapies, either independently or through strategic partnerships and licensing agreements with larger pharmaceutical companies. The company has secured significant funding to advance its pipeline, raising a total of $101 million over three Series A rounds, with investors including Eight Roads Ventures, CBC Group, F-Prime Capital, and Quan Capital.
The company's core offering is its proprietary ADC technology toolbox, which includes the i-Conjugation™ platform, designed to overcome challenges faced by previous generations of ADCs. This technology enables the creation of ADCs with a stable drug-to-antibody ratio, aiming for improved safety and efficacy. Adcentrx's lead product candidate, ADRX-0706, is a Nectin-4 targeting ADC that entered a first-in-human Phase 1a/b clinical trial in the latter half of 2023 for the treatment of advanced solid tumors. Another promising candidate, ADRX-0405, is a potential first-in-class ADC targeting STEAP1 for advanced solid tumors, which received FDA clearance for its Investigational New Drug (IND) application. The company is developing other candidates with the goal of advancing at least one new therapy into the clinic each year.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- San Diego, United States
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 27.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2023 | $13M | $250M | Partners Investment · Quan Capital · Eight Roads Ventures | ↗ |
| SERIES AOther financing | Apr 2023 | $38M | $250M | ABio-X · F-Prime · Delta Capital · Lighthouse Capital | ↗ |
Growth signals
Latest recorded traffic for Adcentrx Therapeutics is 3.1K monthly website visits, up 0% over the last three months. Adcentrx Therapeutics's team declined 10% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Adcentrx Therapeutics in the San Diego ecosystem
The Adcentrx Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
CBC Group
Boyu Capital
Zoo Capital
Eight Roads Ventures
ABio-X
F-Prime- DCDelta Capital
Lighthouse Capital
Trinity Innovation Fund
Partners Investment
Quan Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adcentrx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adcentrx Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









